Immunotherapy in Melanoma | Specialty

Relatlimab/Nivolumab Improves PFS in Previously Untreated Metastatic or Unresectable Melanoma

March 25th 2021

The fixed-dose combination of relatlimab plus nivolumab was found to improve progression-free survival over nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, meeting the primary end point of the phase 2/3 RELATIVITY-047 trial.

Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma

March 19th 2021

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 9th 2021

February 9, 2021 - The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Toripalimab Granted FDA Fast Track Status for Mucosal Melanoma

January 25th 2021

January 25, 2021 - The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.

Dr. Sullivan on Sequencing Targeted Therapy and Immunotherapy in Melanoma

January 13th 2021

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11th 2021

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

FDA Grants Orphan Drug Designation to PVSRIPO for Advanced Melanoma

January 11th 2021

January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.

Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma

January 7th 2021

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Sznol Advocates for More Awareness of Immune-Related Toxicities

December 14th 2020

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

Robert Recaps a Career of Clinical Research in Melanoma

December 7th 2020

In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.